Deferasirox

Spécifications

201530-41-8Numéro CAS

685-491-5Numéro CE

4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acidNom IUPAC

C21H15N3O4Formule chimique

373.4 g/molMasse molaire

Deferasirox; 201530-41-8; Exjade; ICL 670; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; ICL-670A; ICL670; Deferasiroxum; ICL-670; Jadenu; Osveral; Jadenu Sprinkle; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; DTXSID1048596; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; V8G4MOF2V9; CHEBI:49005; DTXCID1028522; Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)-; Deferasorox; Deferasirox oral; RefChem:54942; Deferasirox Oral Granules; V03AC03; 4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid; 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid; ICL670A; ICL 670A; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; Deferasiroxum [INN-Latin]; 1044764-54-6; MFCD09951804; C21H15N3O4; CGP-72670; NCGC00181754-01; 4-{3,5-bis[(1E)-6-oxocyclohexa-2,4-dien-1-ylidene]-1,2,4-triazolidin-1-yl}benzoic acid; 4-(3,5-Bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid; SMR002544689; CAS-201530-41-8; UNII-V8G4MOF2V9; Deferasirox [USAN:INN:JAN]; Deferasirox CRS; HSDB 7844; 4-[3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid; Deferasirox [INN]; Exjade (TN); Jadenu (TN); Deferasirox (Exjade)?; Deferasirox (Standard); Deferasirox, ICL670; Deferasirox 100 microg/mL in Acetonitrile; DEFERASIROX [MI]; Deferasirox (ICL670); DEFERASIROX [JAN]; DEFERASIROX [HSDB]; DEFERASIROX [USAN]; DEFERASIROX [VANDF]; 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid; DEFERASIROX [MART.]; SCHEMBL61756; SCHEMBL62042; DEFERASIROX [USP-RS]; DEFERASIROX [WHO-DD]; MLS003915634; MLS006010080; Deferasirox (JAN/USAN/INN); DEFERASIROX [EMA EPAR]; CHEMBL550348; orb1225750; orb1308568; SCHEMBL1071867; SCHEMBL29381781; DEFERASIROX [ORANGE BOOK]; DEFERASIROX [EP MONOGRAPH]; GLXC-21393; HMS3655A04; HMS5079D16; EX-A4091; Tox21_112926; BDBM50088376; EBC-12794; EBC-50057; HY-17359R; MFCD09751362; s1712; AKOS015855839; AKOS015902587; AKOS025312553; Deferasirox for system suitability CRS; Tox21_112926_1; AC-8972; CCG-268337; CS-0901; DB01609; FB20882; KE-0220; SB18926; Deferasirox(Discontinued,SeeC4X-1438); NCGC00181754-06; NCGC00263572-01; HY-17359; PD087125; SY032012; D5905; NS00000461; SW219752-1; D03669; SBI-0654184.0001; AB01565800_02; EN300-26907573; F387710; SR-01000931971; Q5251502; SR-01000931971-2; BRD-K97010173-001-04-1; F0001-2380; Z3041510169; 4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; 4-(3,5-Bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoicacid; 4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid; 4-[(3z,5e)-3,5-bis(6-oxocyclohexa-2,4-dien-1ylidene)-1,2,4-triazolidin-1-yl] benzoic acid; JBLSynonymes